TrovaGene Inc Share Price Nasdaq
Equities
US8972383090
Biotechnology & Medical Research
Sales 2024 * | 242K 19.42M | Sales 2025 * | 66.67K 5.34M | Capitalization | 199M 15.97B |
---|---|---|---|---|---|
Net income 2024 * | -46M -3.68B | Net income 2025 * | -57M -4.56B | EV / Sales 2024 * | 822 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2,991 x |
P/E ratio 2024 * |
-4.57
x | P/E ratio 2025 * |
-4.23
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.32% |
Latest transcript on TrovaGene Inc
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 03/03/13 |
James Levine
DFI | Director of Finance/CFO | 53 | 11/07/21 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 10/01/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 21/04/20 |
Gary Pace
BRD | Director/Board Member | 76 | 21/04/20 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 03/03/13 |
1st Jan change | Capi. | |
---|---|---|
+0.17% | 42.86B | |
+10.92% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.23% | 25.15B | |
-24.79% | 18.63B | |
+26.69% | 12.37B | |
-3.13% | 11.92B | |
+6.57% | 11.21B |